Vistagen Therapeutics IncNASDAQ:VTGN
- LAST PRICE2.8600
- TODAY'S CHANGE (%)0.1700 (6.3197%)
- Bid / Lots2.8400/ 1
- Ask / Lots2.9000/ 5
- Open / Previous Close2.6900 / 2.6900
- Day Range
- 52 Week Range
- Volume114,963
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTGN |
|---|---|---|
| 09:32 ET | 1168 | 2.67 |
| 09:37 ET | 418 | 2.665 |
| 09:55 ET | 200 | 2.69 |
| 10:06 ET | 15559 | 2.705 |
| 10:09 ET | 100 | 2.6999 |
| 10:11 ET | 100 | 2.6864 |
| 10:15 ET | 1128 | 2.725 |
| 10:18 ET | 233 | 2.725 |
| 10:22 ET | 1885 | 2.74 |
| 10:27 ET | 480 | 2.74 |
| 10:33 ET | 760 | 2.745 |
| 10:36 ET | 200 | 2.745 |
| 10:40 ET | 390 | 2.735 |
| 10:42 ET | 100 | 2.735 |
| 10:44 ET | 2480 | 2.73 |
| 10:45 ET | 200 | 2.73 |
| 10:51 ET | 1524 | 2.75 |
| 11:00 ET | 237 | 2.76 |
| 11:03 ET | 130 | 2.7593 |
| 11:07 ET | 150 | 2.7621 |
| 11:16 ET | 6757 | 2.8 |
| 11:21 ET | 1034 | 2.8185 |
| 11:23 ET | 600 | 2.7926 |
| 11:27 ET | 1774 | 2.83 |
| 11:30 ET | 300 | 2.83 |
| 11:34 ET | 1736 | 2.8525 |
| 11:36 ET | 200 | 2.865 |
| 11:43 ET | 1097 | 2.88 |
| 11:45 ET | 2000 | 2.87 |
| 11:50 ET | 409 | 2.86 |
| 11:52 ET | 300 | 2.86 |
| 11:54 ET | 200 | 2.86 |
| 11:57 ET | 4844 | 2.84 |
| 11:59 ET | 5400 | 2.8301 |
| 12:03 ET | 1000 | 2.83 |
| 12:08 ET | 100 | 2.84 |
| 12:10 ET | 1998 | 2.8405 |
| 12:14 ET | 100 | 2.84 |
| 12:15 ET | 4324 | 2.83 |
| 12:17 ET | 1000 | 2.84 |
| 12:21 ET | 400 | 2.84 |
| 12:24 ET | 3940 | 2.85 |
| 12:26 ET | 1200 | 2.84 |
| 12:32 ET | 400 | 2.845 |
| 12:33 ET | 400 | 2.8442 |
| 12:35 ET | 1942 | 2.84 |
| 12:37 ET | 400 | 2.85 |
| 12:39 ET | 500 | 2.845 |
| 12:42 ET | 800 | 2.845 |
| 12:46 ET | 879 | 2.85 |
| 12:48 ET | 1100 | 2.86 |
| 12:53 ET | 3602 | 2.885 |
| 12:55 ET | 7380 | 2.88 |
| 12:57 ET | 4182 | 2.88 |
| 01:00 ET | 9770 | 2.86 |
Nov 14, 2024
Vistagen to Present at the Stifel 2024 Healthcare Conference, from 8:30AM ET on Thursday Nov 14, 2024 by Dow Jones
8:30AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
*DJ Vistagen Therapeutics 2Q Loss/Shr 42c >VTGN, from 4:20PM ET on Thursday Nov 07, 2024 by Dow Jones
4:20PM ET on Thursday Nov 07, 2024 by Dow JonesVistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update, from 4:20PM ET on Thursday Nov 07, 2024 by Dow Jones
4:20PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Vistagen to Present at the 2024 Neuroscience Education Institute Congress, from 8:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:30AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 1, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vistagen Therapeutics Inc | 74.9M | -2.2x | --- |
Beyondspring Inc | 76.2M | -4.8x | --- |
Ovid Therapeutics Inc | 77.4M | -2.5x | --- |
Unicycive Therapeutics Inc | 70.4M | -3.5x | --- |
Aerovate Therapeutics Inc | 76.2M | -0.9x | --- |
Regencell Bioscience Holdings Ltd | 77.9M | -19.1x | --- |
Company Information
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.
Contact Information
- Headquarters
- 343 ALLERTON AVENUESOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-577-3600
- Fax
- ---
Executives
- Independent Chairman of the Board
- Margaret Fitzpatrick
- Chief Executive Officer, Director
- Shawn Singh
- Chief Financial Officer
- Cynthia Anderson
- Chief Operating Officer
- Joshua Prince
- Senior Vice President - Investor Relations
- Mark Mcpartland
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $74.9M |
|---|---|
Revenue (TTM) | $875.7K |
Shares Outstanding | 27.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.82 |
EPS | $-1.30 |
Book Value | $4.23 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 85.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,207.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
